This content is in French.
4 months to change everything?
24 mars 2025
#Tuberculosis #Diabetes #Rifapentine #ShortCourseTreatment #Moxifloxacin #Safety
Tuberculosis (TB) and diabetes are two major global public health challenges, with high prevalence and significant impacts on morbidity and mortality. When they coexist in the same patient, these conditions negatively and synergistically interact, making management far more complex. Diabetes impairs the immune response, facilitating the progression of TB infection and prolonging recovery. It is also associated with a higher risk of complications, treatment relapse, and even death compared to non-diabetic patients.
Tuberculosis (TB) and diabetes are two major global public health challenges, with high prevalence and significant impacts on morbidity and mortality. When they coexist in the same patient, these conditions negatively and synergistically interact, making management far more complex. Diabetes impairs the immune response, facilitating the progression of TB infection and prolonging recovery. It is also associated with a higher risk of complications, treatment relapse, and even death compared to non-diabetic patients.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Kurbatova, E. V., et al. Tuberculosis Trials Consortium Study 31 (2025). Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes. Emerging infectious diseases, 31(3), 467–476
View the source
